Table 2 Patient baseline demographics and clinical characteristics
|  |  | Non-liver metastasis group | Liver metastasis group | χ2/t | P |
|---|---|---|---|---|---|
Sexa | Male | 112 (67.07%) | 107 (64.07%) | 0.332 | 0.565 |
| Â | Female | 55 (32.93%) | 60 (35.93%) | Â | Â |
Agea (years) |  | 53.49 ± 14.49 | 57.44 ± 13.55 | 1.568 | 0.093 |
Primary lesionsa | Transverse colon cancer | 10 (2.99%) | 14 (8.38%) | 4.498 | 0.480 |
| Â | Lower colon cancer | 15 (4, 49%) | 9 (5.39%) | Â | Â |
| Â | Colon cancer | 39 (11.68%) | 32 (19.17%) | Â | Â |
| Â | sigmoid colon cancer | 56 (16.77%) | 54 (32.33%) | Â | Â |
| Â | Rectal cancer | 47 (14.07%) | 58 (34.73%) | Â | Â |
Tumour markerb | Abnormal CEA | 114 (62.26%) | 147 (88.02%) | 19.090 | 0.001* |
Abnormal CA125 | 99 (59.28%) | 128 (76.65%) | 11.565 | 0.001* | |
| Â | Abnormal CA19-9 | 117 (70.06%) | 142 (85.03%) | 10.746 | 0.001* |